PTGX CMO exercises options, sells 23,151 shares

Protagonist Therapeutics Chief Medical Officer Arturo Molina reported multiple stock option exercises and share sales.

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Medical Officer Arturo Molina reported multiple stock option exercises and share sales. On January 26 and 27, 2026, he exercised a total of 10,000 stock options at an exercise price of $8.04 per share and acquired the same number of common shares.

He then sold 5,000 shares on each of January 26 and 27 at weighted average prices of $82.28 and $82 per share, and earlier sold 13,151 shares on January 23, 2026 at a weighted average price of $82.42 per share. After these transactions he directly owned 84,115 common shares and 65,971 stock options, with the option grant originally covering 127,500 shares and vesting through November 7, 2026.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider MOLINA ARTURO MD

Role Chief Medical Officer

Sold 23,151 shs ($1.91M)

Approx. gross sale proceeds $1.91M

Approx. exercise cost $80K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$8.04	$40K
Sale	Common Stock	5,000	$82.00	$410K
Exercise	Stock Option (right to buy)	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$8.04	$40K
Sale	Common Stock	5,000	$82.28	$411K
Sale	Common Stock	13,151	$82.42	$1.08M

Holdings After Transaction: Stock Option (right to buy) — 65,971 contracts (Direct); Common Stock — 84,115 shares (Direct)

Footnotes (3)

1. F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.665 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.14 to $82.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.

FAQ

What insider transactions did PTGX Chief Medical Officer Arturo Molina report?

Arturo Molina reported exercising stock options and selling common shares. He exercised 10,000 options at $8.04 per share, then sold 23,151 shares at weighted average prices around $82–$84, and ended with 84,115 shares directly owned plus 65,971 options.

How many Protagonist Therapeutics (PTGX) shares did Arturo Molina sell?

Arturo Molina sold a total of 23,151 PTGX shares. This included 13,151 shares sold on January 23, 2026 and two blocks of 5,000 shares sold on January 26 and 27, 2026 at weighted average prices slightly above $82 per share.

At what prices did Arturo Molina’s PTGX stock sales occur?

His reported sale prices were weighted averages. On January 23, 2026, shares sold at $82.42, with trades ranging from $82.665 to $84.64. On January 26, sales averaged $82.28, and on January 27, the reported sale price was $82 per share.

How many Protagonist Therapeutics shares does Arturo Molina own after these trades?

Following the reported transactions, Arturo Molina directly owns 84,115 shares of Protagonist Therapeutics common stock. He also holds 65,971 stock options remaining from an original 127,500-share option grant that continues vesting through November 7, 2026.

What stock options did Arturo Molina exercise in this Form 4 for PTGX?

He exercised 5,000 stock options on January 26, 2026 and another 5,000 on January 27, 2026. All were from an option with an $8.04 exercise price, originally covering 127,500 shares and vesting in tranches through November 7, 2026.

What does the weighted average sale price mean in Molina’s PTGX transactions?

The weighted average sale price reflects multiple trades at different prices on the same day. For January 23, 2026, prices ranged from $82.665 to $84.64; for January 26, prices ranged from $82.14 to $82.55, with Molina offering to provide full breakdowns on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 09:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOLINA ARTURO MD

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		S		13,151	D	$82.42(1)	84,115	D
Common Stock	01/26/2026		M		5,000	A	$8.04	89,115	D
Common Stock	01/26/2026		S		5,000	D	$82.28(2)	84,115	D
Common Stock	01/27/2026		M		5,000	A	$8.04	89,115	D
Common Stock	01/27/2026		S		5,000	D	$82	84,115	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.04	01/26/2026		M			5,000	(3)	11/15/2032	Common Stock	5,000	$0.00	70,971	D
Stock Option (right to buy)	$8.04	01/27/2026		M			5,000	(3)	11/15/2032	Common Stock	5,000	$0.00	65,971	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.665 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.14 to $82.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.